Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-11-18

Clinical Trial Update: Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy [Phase 4]

View source ↗

Summary

Phase 4 study evaluating rituximab in progressive IgA nephropathy completed; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rituxan (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: IgA Nephropathy | Phase 4 | Status: COMPLETED | Results posted: 2016-11-18